Source: Korea Biomedical Review

Eli Lilly: Lilly's Olumiant proves fast symptom improvement in atopic dermatitis

Eli Lilly's Olumiant (ingredient: baricitinib), the first Janus kinase (JAK) inhibitor to win approval for atopic dermatitis (AD) treatment in Korea, has not only offered convenience as an oral drug but proved quick symptom improvement, the company said.Lilly Korea held a symposium on June 3 to shar

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
$25.5B
Employees
38,680
David A. Ricks's photo - Chairman & CEO of Eli Lilly

Chairman & CEO

David A. Ricks

CEO Approval Rating

65/100

Read more